CHUV-DO-PART-2016: Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment
Indication :

Cancer du sein, du poumon ou métastases pulmonaires


Sponsor :

CHUV


Phase :

II


Spécificités :

Etude pilote pour évaluer le gain dosimétrique de la ventilation percussive pour la radiothérapie des cancers du poumon, du sein et des cancers d’origine digestive oligométastatique au foie


Site :

CHUV


Contact(s) :
Prof. Jean Bourhis
Investigateur principal

CHUV
Radio-Oncologie

Rue de Bugnon 46
Lausanne
1011

021 314 46 65
jean.bourhis@chuv.ch

Primary objective :

The main objective of the trial is to demonstrate the clinical benefit of the HFPV coupled to thoracic radiotherapy in 2 distinct and frequent clinical situations :

  1. Tomotherapy for lung and left breast tumors. The investigators assume that the volume of irradiated healthy tissue will be much less when using HFPV as compared to free breathing during tomotherapy sessions.
  2. In comparison with Active Breathing Control (ABC system). The investigators assume that the HFPV will lead to breathing motions cessation the same way as the ABC system, but will abrogate pause times when administrating the radiotherapy. This will shorten the radiotherapy sessions for lung patients treated with stereotaxis and for breast cancer patients.

Inclusion criteria :
  1. Breast cancer eligible for tomotherapy or linear accelerator with ABC system
  2. Lung cancer eligible for curative tomotherapy and with breathing movements amplitude >1 cm
  3. Lung cancer eligible for ablative stereotaxis
  4. WHO 0 or 1

Exclusion criteria :
  1. Patients requiring oxygen or not able to lie on the back (dyspnea)
  2. Ppulmonary functions altered
  3. Cardiac insufficiency
  4. Patient not able to breathe with the High Frequency Ventilation System
  5. Risk of pneumothorax when experiencing High Frequency Ventilation